Lantern Pharma is trading 11.76% higher at $1.52 after announcing a USPTO Notice of Allowance for an LP-284 treatment patent covering aggressive B-cell lymphomas.
- A September 23 Open-Medicine AI webinar may also be adding investor interest.
- Broader biotech strength, including a 2.07% XBI gain, provides additional support.